

# Thomas Mandrup-Poulsen

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3935451/publications.pdf>

Version: 2024-02-01

175  
papers

15,003  
citations

17405

63  
h-index

18606

119  
g-index

181  
all docs

181  
docs citations

181  
times ranked

16348  
citing authors

#	ARTICLE	IF	CITATIONS
1	Celebrities in the heart, strangers in the pancreatic beta cell: Voltage-gated potassium channels $K_{v}7.1$ and $K_{v}11.1$ bridge long QT syndrome with hyperinsulinaemia as well as type 2 diabetes. <i>Acta Physiologica</i> , 2022, 234, e13781.	1.8	6
2	Defective Proinsulin Handling Modulates the MHC I Bound Peptidome and Activates the Inflammasome in $\beta$ -Cells. <i>Biomedicines</i> , 2022, 10, 814.	1.4	3
3	Age-dependent transition from islet insulin hypersecretion to hyposcretion in mice with the long QT-syndrome loss-of-function mutation <i>Kcnq1-A340V</i> . <i>Scientific Reports</i> , 2021, 11, 12253.	1.6	10
4	Divalent Metal Transporter 1 Knock-Down Modulates IL-1 $\beta$ Mediated Pancreatic Beta-Cell Pro-Apoptotic Signaling Pathways through the Autophagic Machinery. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8013.	1.8	4
5	Proinflammatory Cytokines Perturb Mouse and Human Pancreatic Islet Circadian Rhythmicity and Induce Uncoordinated $\beta$ -Cell Clock Gene Expression via Nitric Oxide, Lysine Deacetylases, and Immunoproteasomal Activity. <i>International Journal of Molecular Sciences</i> , 2021, 22, 83.	1.8	6
6	Interleukin-6 receptor blockade or TNF $\pm$ inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials. <i>Arthritis Research and Therapy</i> , 2020, 22, 206.	1.6	20
7	Enhancer of Zeste Homolog 2 (EZH2) Mediates Glucolipototoxicity-Induced Apoptosis in $\beta$ -Cells. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8016.	1.8	3
8	The Connexin 43 Regulator Rotigaptide Reduces Cytokine-Induced Cell Death in Human Islets. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4311.	1.8	5
9	The intermediate proteasome is constitutively expressed in pancreatic beta cells and upregulated by stimulatory, low concentrations of interleukin 1 $\beta$ . <i>PLoS ONE</i> , 2020, 15, e0222432.	1.1	13
10	The inducible $\beta$ 5i proteasome subunit contributes to proinsulin degradation in GRP94-deficient $\beta$ -cells and is overexpressed in type 2 diabetes pancreatic islets. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2020, 318, E892-E900.	1.8	7
11	Mitophagy protects $\beta$ cells from inflammatory damage in diabetes. <i>JCI Insight</i> , 2020, 5, .	2.3	67
12	Combination of ferric ammonium citrate with cytokines involved in apoptosis and insulin secretion of human pancreatic beta cells related to diabetes in thalassemia. <i>PeerJ</i> , 2020, 8, e9298.	0.9	1
13	Title is missing!. , 2020, 15, e0222432.		0
14	Title is missing!. , 2020, 15, e0222432.		0
15	Title is missing!. , 2020, 15, e0222432.		0
16	Title is missing!. , 2020, 15, e0222432.		0
17	Title is missing!. , 2020, 15, e0222432.		0
18	Title is missing!. , 2020, 15, e0222432.		0

#	ARTICLE	IF	CITATIONS
19	Urinary nucleic acid oxidation product levels show differential associations with pharmacological treatment in patients with type 2 diabetes. <i>Free Radical Research</i> , 2019, 53, 694-703.	1.5	5
20	The Lysine Demethylase KDM5B Regulates Islet Function and Glucose Homeostasis. <i>Journal of Diabetes Research</i> , 2019, 2019, 1-15.	1.0	15
21	Targeting innate immune mediators in type 1 and type 2 diabetes. <i>Nature Reviews Immunology</i> , 2019, 19, 734-746.	10.6	237
22	Endoplasmic Reticulum Chaperone Glucose-Regulated Protein 94 Is Essential for Proinsulin Handling. <i>Diabetes</i> , 2019, 68, 747-760.	0.3	52
23	Treatment of type 2 diabetes by targeting interleukin-1: a meta-analysis of 2921 patients. <i>Seminars in Immunopathology</i> , 2019, 41, 413-425.	2.8	28
24	No direct effect of SGLT2 activity on glucagon secretion. <i>Diabetologia</i> , 2019, 62, 1011-1023.	2.9	58
25	Neuromedin U Does Not Act as a Decretin in Rats. <i>Cell Metabolism</i> , 2019, 29, 719-726.e5.	7.2	9
26	Metabolism and the inflammasome in health and ageing. <i>Nature Reviews Endocrinology</i> , 2018, 14, 72-74.	4.3	9
27	Lysine demethylase inhibition protects pancreatic $\beta$ cells from apoptosis and improves $\beta$ -cell function. <i>Molecular and Cellular Endocrinology</i> , 2018, 460, 47-56.	1.6	22
28	Oral histone deacetylase inhibitor synergises with T cell targeted immunotherapy to preserve beta cell metabolic function and induce stable remission of new-onset autoimmune diabetes in NOD mice. <i>Diabetologia</i> , 2018, 61, 389-398.	2.9	16
29	Increased Plasma Ferritin Concentration and Low-Grade Inflammation—A Mendelian Randomization Study. <i>Clinical Chemistry</i> , 2018, 64, 374-385.	1.5	24
30	MicroRNAs and histone deacetylase inhibition-mediated protection against inflammatory $\beta$ -cell damage. <i>PLoS ONE</i> , 2018, 13, e0203713.	1.1	17
31	The No-Go and Nonsense-Mediated RNA Decay Pathways Are Regulated by Inflammatory Cytokines in Insulin-Producing Cells and Human Islets and Determine $\beta$ -Cell Insulin Biosynthesis and Survival. <i>Diabetes</i> , 2018, 67, 2019-2037.	0.3	16
32	Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue. <i>Journal of Biological Chemistry</i> , 2018, 293, 14224-14236.	1.6	42
33	Acute administration of interleukin-6 does not increase secretion of glucagon-like peptide-1 in mice. <i>Physiological Reports</i> , 2018, 6, e13788.	0.7	8
34	Iron Status and Gestational Diabetes—A Meta-Analysis. <i>Nutrients</i> , 2018, 10, 621.	1.7	52
35	Glucolipotoxic conditions induce $\beta$ -cell iron import, cytosolic ROS formation and apoptosis. <i>Journal of Molecular Endocrinology</i> , 2018, 61, 69-77.	1.1	44
36	Regulation of the $\beta$ -cell inflammasome and contribution to stress-induced cellular dysfunction and apoptosis. <i>Molecular and Cellular Endocrinology</i> , 2018, 478, 106-114.	1.6	19

#	ARTICLE	IF	CITATIONS
37	The immunoproteasome is induced by cytokines and regulates apoptosis in human islets. <i>Journal of Endocrinology</i> , 2017, 233, 369-379.	1.2	26
38	Cardiovascular and All-Cause Mortality Risk Associated With Urinary Excretion of 8-oxoGuo, a Biomarker for RNA Oxidation, in Patients With Type 2 Diabetes: A Prospective Cohort Study. <i>Diabetes Care</i> , 2017, 40, 1771-1778.	4.3	51
39	A guiding map for inflammation. <i>Nature Immunology</i> , 2017, 18, 826-831.	7.0	506
40	Granzyme A in the Pathogenesis of Type 1 Diabetes: The Yes and the No. <i>Diabetes</i> , 2017, 66, 2937-2939.	0.3	4
41	JNK1 Deficient Insulin-Producing Cells Are Protected against Interleukin-1 $\beta$ -Induced Apoptosis Associated with Abrogated Myc Expression. <i>Journal of Diabetes Research</i> , 2016, 2016, 1-15.	1.0	9
42	A Systematic Comparison of Purification and Normalization Protocols for Quantitative MicroRNA Expressional Profiling in Insulin-Producing Cells. <i>International Journal of Molecular Sciences</i> , 2016, 17, 896.	1.8	1
43	Interleukin-1 antagonist moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset. <i>European Journal of Immunology</i> , 2016, 46, 1030-1046.	1.6	54
44	Iron Regulation of Pancreatic Beta-Cell Functions and Oxidative Stress. <i>Annual Review of Nutrition</i> , 2016, 36, 241-273.	4.3	73
45	MicroRNAs as regulators of beta-cell function and dysfunction. <i>Diabetes/Metabolism Research and Reviews</i> , 2016, 32, 334-349.	1.7	62
46	Cytokines and Pancreatic $\beta$ -Cell Apoptosis. <i>Advances in Clinical Chemistry</i> , 2016, 75, 99-158.	1.8	85
47	An Isochemogenic Set of Inhibitors To Define the Therapeutic Potential of Histone Deacetylases in $\beta$ -Cell Protection. <i>ACS Chemical Biology</i> , 2016, 11, 363-374.	1.6	78
48	TRAF2 mediates JNK and STAT3 activation in response to IL-1 $\beta$ and IFN $\gamma$ and facilitates apoptotic death of insulin-producing $\beta$ -cells. <i>Molecular and Cellular Endocrinology</i> , 2016, 420, 24-36.	1.6	19
49	A Placebo-Controlled Study on the Effects of the Glucagon-Like Peptide-1 Mimetic, Exenatide, on Insulin Secretion, Body Composition and Adipokines in Obese, Client-Owned Cats. <i>PLoS ONE</i> , 2016, 11, e0154727.	1.1	7
50	Skeletal Muscle to Pancreatic $\beta$ -Cell Cross-talk: The Effect of Humoral Mediators Liberated by Muscle Contraction and Acute Exercise on $\beta$ -Cell Apoptosis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2015, 100, E1289-E1298.	1.8	39
51	Over-expression of Follistatin-like 3 attenuates fat accumulation and improves insulin sensitivity in mice. <i>Metabolism: Clinical and Experimental</i> , 2015, 64, 283-295.	1.5	41
52	Helsinki alert of biodiversity and health. <i>Annals of Medicine</i> , 2015, 47, 218-225.	1.5	95
53	Histone deacetylase 3 inhibition improves glycaemia and insulin secretion in obese diabetic rats. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 703-707.	2.2	90
54	HDAC Inhibitor-Mediated Beta-Cell Protection Against Cytokine-Induced Toxicity Is STAT1 Tyr701 Phosphorylation Independent. <i>Journal of Interferon and Cytokine Research</i> , 2015, 35, 63-70.	0.5	11

#	ARTICLE	IF	CITATIONS
55	Tissue Inhibitor Of Matrix Metalloproteinase-1 Is Required for High-Fat Diet-Induced Glucose Intolerance and Hepatic Steatosis in Mice. PLoS ONE, 2015, 10, e0132910.	1.1	9
56	JNK1 Protects against Glucolipototoxicity-Mediated Beta-Cell Apoptosis. PLoS ONE, 2014, 9, e87067.	1.1	33
57	Indomethacin Treatment Prevents High Fat Diet-induced Obesity and Insulin Resistance but Not Glucose Intolerance in C57BL/6J Mice. Journal of Biological Chemistry, 2014, 289, 16032-16045.	1.6	33
58	Altering $\beta$ -cell number through stable alteration of miR-21 and miR-34a expression. Islets, 2014, 6, e27754.	0.9	42
59	Total and Cause-Specific Mortality by Elevated Transferrin Saturation and Hemochromatosis Genotype in Individuals With Diabetes: Two General Population Studies. Diabetes Care, 2014, 37, 444-452.	4.3	10
60	Need for Reclassification of Diabetes Secondary to Iron Overload in the ADA and WHO Classifications. Diabetes Care, 2014, 37, e137-e138.	4.3	5
61	Interleukin-1 Antagonism: A Sturdy Companion for Immune Tolerance Induction in Type 1 Diabetes?. Diabetes, 2014, 63, 1833-1835.	0.3	5
62	Inhibition of beta cell growth and function by bone morphogenetic proteins. Diabetologia, 2014, 57, 2546-2554.	2.9	33
63	Age-dependent decline of $\beta$ -cell function in type 1 diabetes after diagnosis: a multicentre longitudinal study. Diabetes, Obesity and Metabolism, 2014, 16, 262-267.	2.2	79
64	Iron: the hard player in diabetes pathophysiology. Acta Physiologica, 2014, 210, 717-732.	1.8	105
65	Anti-inflammatory properties of a novel peptide interleukin 1 receptor antagonist. Journal of Neuroinflammation, 2014, 11, 27.	3.1	26
66	Skeletal muscle apolipoprotein B expression reduces muscular triglyceride accumulation. Scandinavian Journal of Clinical and Laboratory Investigation, 2014, 74, 351-357.	0.6	6
67	Lysine deacetylase inhibition prevents diabetes by chromatin-independent immunoregulation and $\beta$ -cell protection. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 1055-1059.	3.3	58
68	Type 2 Diabetes Mellitus. Dermatologic Clinics, 2013, 31, 495-506.	1.0	23
69	Anti-cytokine therapies in T1D: Concepts and strategies. Clinical Immunology, 2013, 149, 279-285.	1.4	56
70	Serum adipokines as biomarkers of beta-cell function in patients with type 1 diabetes: positive association with leptin and resistin and negative association with adiponectin. Diabetes/Metabolism Research and Reviews, 2013, 29, 166-170.	1.7	35
71	Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet, The, 2013, 381, 1905-1915.	6.3	301
72	Interleukin-1 antagonists for diabetes. Expert Opinion on Investigational Drugs, 2013, 22, 965-979.	1.9	13

#	ARTICLE	IF	CITATIONS
73	Total Mortality by Elevated Transferrin Saturation in Patients With Diabetes. <i>Diabetes Care</i> , 2013, 36, 2646-2654.	4.3	13
74	The lysine deacetylase inhibitor givinostat inhibits $\beta$ -cell IL-1 $\beta$ induced IL-1 $\beta$ transcription and processing. <i>Islets</i> , 2012, 4, 417-422.	0.9	12
75	Effects of Gevokizumab on Glycemia and Inflammatory Markers in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 1654-1662.	4.3	237
76	Perspective: Testing failures. <i>Nature</i> , 2012, 485, S17-S17.	13.7	3
77	TiSH "a robust and sensitive global phosphoproteomics strategy employing a combination of TiO <sub>2</sub> , SIMAC, and HILIC. <i>Journal of Proteomics</i> , 2012, 75, 5749-5761.	1.2	174
78	Divalent Metal Transporter 1 Regulates Iron-Mediated ROS and Pancreatic $\beta$ Cell Fate in Response to Cytokines. <i>Cell Metabolism</i> , 2012, 16, 449-461.	7.2	133
79	<sup>19</sup> F-heptuloses as tools for the non-invasive imaging of GLUT2-expressing cells. <i>Archives of Biochemistry and Biophysics</i> , 2012, 517, 138-143.	1.4	16
80	Transcriptional and translational regulation of cytokine signaling in inflammatory $\beta$ -cell dysfunction and apoptosis. <i>Archives of Biochemistry and Biophysics</i> , 2012, 528, 171-184.	1.4	32
81	Histone deacetylases 1 and 3 but not 2 mediate cytokine-induced beta cell apoptosis in INS-1 cells and dispersed primary islets from rats and are differentially regulated in the islets of type 1 diabetic children. <i>Diabetologia</i> , 2012, 55, 2421-2431.	2.9	77
82	Synergistic Reversal of Type 1 Diabetes in NOD Mice With Anti-CD3 and Interleukin-1 Blockade. <i>Diabetes</i> , 2012, 61, 145-154.	0.3	98
83	RNA modifications by oxidation: A novel disease mechanism?. <i>Free Radical Biology and Medicine</i> , 2012, 52, 1353-1361.	1.3	174
84	Interleukin-1 Antagonists and Other Cytokine Blockade Strategies for Type 1 Diabetes. <i>Review of Diabetic Studies</i> , 2012, 9, 338-347.	0.5	16
85	Histone Deacetylase (HDAC) Inhibition as a Novel Treatment for Diabetes Mellitus. <i>Molecular Medicine</i> , 2011, 17, 378-390.	1.9	217
86	The Oral Histone Deacetylase Inhibitor ITF2357 Reduces Cytokines and Protects Islet $\beta$ Cells In Vivo and In Vitro. <i>Molecular Medicine</i> , 2011, 17, 369-377.	1.9	99
87	Direct demonstration of NCAM cis-dimerization and inhibitory effect of palmitoylation using the BRET <sup>2</sup> technique. <i>FEBS Letters</i> , 2011, 585, 58-64.	1.3	9
88	Apolipoprotein CIII Reduces Proinflammatory Cytokine-Induced Apoptosis in Rat Pancreatic Islets via the Akt Prosurvival Pathway. <i>Endocrinology</i> , 2011, 152, 3040-3048.	1.4	20
89	Cytokines and Type 1 Diabetes: A Numbers Game. <i>Diabetes</i> , 2011, 60, 697-699.	0.3	21
90	Elevated Transferrin Saturation and Risk of Diabetes: Three population-based studies. <i>Diabetes Care</i> , 2011, 34, 2256-2258.	4.3	60

#	ARTICLE	IF	CITATIONS
91	Endothelial Progenitor Cells in Long-Standing Asymptomatic Type 1 Diabetic Patients with or without Diabetic Nephropathy. <i>Nephron Clinical Practice</i> , 2011, 118, c309-c314.	2.3	8
92	Role of IL-1 $\beta$ in type 2 diabetes. <i>Current Opinion in Endocrinology, Diabetes and Obesity</i> , 2010, 17, 314-321.	1.2	284
93	Blockade of interleukin 1 in type 1 diabetes mellitus. <i>Nature Reviews Endocrinology</i> , 2010, 6, 158-166.	4.3	204
94	The global diabetes epidemic as a consequence of lifestyle-induced low-grade inflammation. <i>Diabetologia</i> , 2010, 53, 10-20.	2.9	252
95	Lysine deacetylases are produced in pancreatic beta cells and are differentially regulated by proinflammatory cytokines. <i>Diabetologia</i> , 2010, 53, 2569-2578.	2.9	66
96	Serum Proteome Pool Changes in Type 2 Diabetic Patients Treated with Anakinra. <i>Clinical Proteomics</i> , 2010, 6, 153-161.	1.1	1
97	IAPP boosts islet macrophage IL-1 in type 2 diabetes. <i>Nature Immunology</i> , 2010, 11, 881-883.	7.0	33
98	High Glucose Suppresses Human Islet Insulin Biosynthesis by Inducing miR-133a Leading to Decreased Polypyrimidine Tract Binding Protein-Expression. <i>PLoS ONE</i> , 2010, 5, e10843.	1.1	76
99	Proinflammatory Cytokines Activate the Intrinsic Apoptotic Pathway in $\beta$ -Cells. <i>Diabetes</i> , 2009, 58, 1807-1815.	0.3	195
100	Sustained Effects of Interleukin-1 Receptor Antagonist Treatment in Type 2 Diabetes. <i>Diabetes Care</i> , 2009, 32, 1663-1668.	4.3	347
101	Inhibition of Nuclear Factor- $\kappa$ B or Bax Prevents Endoplasmic Reticulum Stress- But Not Nitric Oxide-Mediated Apoptosis in INS-1E Cells. <i>Endocrinology</i> , 2009, 150, 4094-4103.	1.4	31
102	Suppressor of cytokine signalling-3 inhibits tumor necrosis factor-alpha induced apoptosis and signalling in beta cells. <i>Molecular and Cellular Endocrinology</i> , 2009, 311, 32-38.	1.6	35
103	IL-1 receptor antagonism and muscle gene expression in patients with type 2 diabetes. <i>European Cytokine Network</i> , 2009, 20, 81-87.	1.1	11
104	G Protein-Coupled Receptor 39 Deficiency Is Associated with Pancreatic Islet Dysfunction. <i>Endocrinology</i> , 2009, 150, 2577-2585.	1.4	82
105	The use of interleukin-1-receptor antagonists in the treatment of diabetes mellitus. <i>Nature Clinical Practice Endocrinology and Metabolism</i> , 2008, 4, 240-241.	2.9	37
106	Mixed-Meal Tolerance Test Versus Glucagon Stimulation Test for the Assessment of $\beta$ -Cell Function in Therapeutic Trials in Type 1 Diabetes. <i>Diabetes Care</i> , 2008, 31, 1966-1971.	4.3	250
107	Cytokines and $\beta$ -Cell Biology: from Concept to Clinical Translation. <i>Endocrine Reviews</i> , 2008, 29, 334-350.	8.9	201
108	The Fas pathway is involved in pancreatic beta cell secretory function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2007, 104, 2861-2866.	3.3	83

#	ARTICLE	IF	CITATIONS
109	Diabetes and Suppressors of Cytokine Signaling Proteins. <i>Diabetes</i> , 2007, 56, 541-548.	0.3	54
110	Interleukin-1 $\beta$ Receptor Antagonist in Type 2 Diabetes Mellitus. <i>New England Journal of Medicine</i> , 2007, 356, 1517-1526.	13.9	1,579
111	Inhibition of histone deacetylases prevents cytokine-induced toxicity in beta cells. <i>Diabetologia</i> , 2007, 50, 779-789.	2.9	123
112	Proliferation of sorted human and rat beta cells. <i>Diabetologia</i> , 2007, 51, 91-100.	2.9	213
113	Cytokine-Induced Proapoptotic Gene Expression in Insulin-Producing Cells Is Related to Rapid, Sustained, and Nonoscillatory Nuclear Factor- $\kappa$ B Activation. <i>Molecular Endocrinology</i> , 2006, 20, 1867-1879.	3.7	124
114	RX871024 reduces NO production but does not protect against pancreatic $\beta$ -cell death induced by proinflammatory cytokines. <i>Biochemical and Biophysical Research Communications</i> , 2006, 347, 1121-1128.	1.0	12
115	Suppressor of Cytokine Signaling-3 Inhibits Interleukin-1 Signaling by Targeting the TRAF-6/TAK1 Complex. <i>Molecular Endocrinology</i> , 2006, 20, 1587-1596.	3.7	153
116	Cytokines Downregulate the Sarcoendoplasmic Reticulum Pump Ca <sup>2+</sup> ATPase 2b and Deplete Endoplasmic Reticulum Ca <sup>2+</sup> , Leading to Induction of Endoplasmic Reticulum Stress in Pancreatic $\beta$ -Cells. <i>Diabetes</i> , 2005, 54, 452-461.	0.3	471
117	Variations of the interleukin-6 promoter are associated with features of the metabolic syndrome in Caucasian Danes. <i>Diabetologia</i> , 2005, 48, 251-260.	2.9	144
118	Extracellular signal-regulated kinase is essential for interleukin-1-induced and nuclear factor $\kappa$ B-mediated gene expression in insulin-producing INS-1E cells. <i>Diabetologia</i> , 2005, 48, 2582-2590.	2.9	55
119	An immune origin of type 2 diabetes?. <i>Diabetologia</i> , 2005, 48, 1038-1050.	2.9	384
120	Nitric oxide contributes to cytokine-induced apoptosis in pancreatic beta cells via potentiation of JNK activity and inhibition of Akt. <i>Diabetologia</i> , 2005, 48, 2039-2050.	2.9	130
121	Interleukin-6 and Diabetes: The Good, the Bad, or the Indifferent?. <i>Diabetes</i> , 2005, 54, S114-S124.	0.3	442
122	Calcium Has a Permissive Role in Interleukin-1 $\beta$ -Induced c-Jun N-Terminal Kinase Activation in Insulin-Secreting Cells. <i>Endocrinology</i> , 2005, 146, 3026-3036.	1.4	34
123	Antitumorigenic Effect of Proteasome Inhibitors on Insulinoma Cells. <i>Endocrinology</i> , 2005, 146, 1718-1726.	1.4	12
124	Is Puberty an Accelerator of Type 1 Diabetes in IL6-174CC Females?. <i>Diabetes</i> , 2005, 54, 1245-1248.	0.3	27
125	Poor Pregnancy Outcome in Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2005, 28, 323-328.	4.3	255
126	Glucose- and Interleukin-1 $\beta$ -Induced $\beta$ -Cell Apoptosis Requires Ca <sup>2+</sup> Influx and Extracellular Signal-Regulated Kinase (ERK) 1/2 Activation and Is Prevented by a Sulfonylurea Receptor 1/Inwardly Rectifying K <sup>+</sup> Channel 6.2 (SUR/Kir6.2) Selective Potassium Channel Opener in Human Islets. <i>Diabetes</i> , 2004, 53, 1706-1713.	0.3	149



#	ARTICLE	IF	CITATIONS
127	Suppressor of cytokine signalling (SOCS)-3 protects beta cells against IL-1 $\beta$ -mediated toxicity through inhibition of multiple nuclear factor- $\kappa$ B-regulated proapoptotic pathways. <i>Diabetologia</i> , 2004, 47, 1998-2011.	2.9	51
128	Beta Cell Death and Protection. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 32-42.	1.8	75
129	Mutation Scan of a Type 1 Diabetes Candidate Gene. <i>Annals of the New York Academy of Sciences</i> , 2003, 1005, 332-339.	1.8	5
130	Inflammatory mediators and islet $\beta$ -cell failure: a link between type 1 and type 2 diabetes. <i>Journal of Molecular Medicine</i> , 2003, 81, 455-470.	1.7	379
131	Apoptotic signal transduction pathways in diabetes. <i>Biochemical Pharmacology</i> , 2003, 66, 1433-1440.	2.0	126
132	Calcium- and Proteasome-dependent Degradation of the JNK Scaffold Protein Islet-brain 1. <i>Journal of Biological Chemistry</i> , 2003, 278, 48720-48726.	1.6	18
133	Association of a functional 17 $\beta$ -estradiol sensitive IL6-174G/C promoter polymorphism with early-onset type 1 diabetes in females. <i>Human Molecular Genetics</i> , 2003, 12, 1101-1110.	1.4	43
134	IA-2 Antibody-Negative Status Predicts Remission and Recovery of C-Peptide Levels in Type 1 Diabetic Patients Treated With Cyclosporin. <i>Diabetes Care</i> , 2002, 25, 1192-1197.	4.3	17
135	Process measures and outcome research as tools for future improvement of diabetes treatment quality. <i>Diabetes Research and Clinical Practice</i> , 2002, 56, 207-211.	1.1	7
136	IL-1 $\beta$ induced protein changes in diabetes prone BB rat islets of Langerhans identified by proteome analysis. <i>Diabetologia</i> , 2002, 45, 1550-1561.	2.9	65
137	Prevalence of hereditary haemochromatosis in late-onset type 1 diabetes mellitus: a retrospective study. <i>Lancet, The</i> , 2001, 358, 1405-1409.	6.3	117
138	Attitudes towards diabetes and its care: Evaluation before, immediately post-course and 1 year after a practical, international inter-disciplinary course for diabetes teams.. <i>Practical Diabetes International: the International Journal for Diabetes Care Teams Worldwide</i> , 2001, 18, 39-44.	0.2	3
139	A choice of death - the signal-transduction of immune-mediated beta-cell apoptosis. <i>Diabetologia</i> , 2001, 44, 2115-2133.	2.9	782
140	Suppressor of cytokine signaling 3 (SOCS-3) protects $\beta$ -cells against interleukin-1 $\beta$ - and interferon- $\gamma$ -mediated toxicity. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001, 98, 12191-12196.	3.3	131
141	The intercellular adhesion molecule-1 K469E polymorphism in type 1 diabetes. <i>Immunogenetics</i> , 2000, 52, 107-111.	1.2	27
142	Interferon- $\gamma$ Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 830-836.	1.8	49
143	LINKAGE DISEQUILIBRIUM TESTING OF FOUR INTERLEUKIN-1 GENE-CLUSTER POLYMORPHISMS IN DANISH MULTIPLEX FAMILIES WITH INSULIN-DEPENDENT DIABETES MELLITUS. <i>Cytokine</i> , 2000, 12, 171-175.	1.4	18
144	GLUTATHIONE DEPLETION INHIBITS IL-1 $\beta$ -STIMULATED NITRIC OXIDE PRODUCTION BY REDUCING INDUCIBLE NITRIC OXIDE SYNTHASE GENE EXPRESSION. <i>Cytokine</i> , 2000, 12, 1391-1394.	1.4	21

#	ARTICLE	IF	CITATIONS
145	Interferon- $\gamma$ Induces Interleukin-1 Converting Enzyme Expression in Pancreatic Islets by an Interferon Regulatory Factor-1-Dependent Mechanism. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2000, 85, 830-836.	1.8	45
146	Absence of toxicity associated with adenoviral-mediated transfer of the $\beta$ -galactosidase reporter gene to neonatal rat islets in vitro. <i>Diabetes Research and Clinical Practice</i> , 1999, 44, 157-163.	1.1	9
147	Apoptosis and the pathogenesis of IDDM: a question of life and death. <i>Diabetes</i> , 1998, 47, 1537-1543.	0.3	141
148	Ciliary neurotrophic factor potentiates the beta-cell inhibitory effect of IL-1 $\beta$ in rat pancreatic islets associated with increased nitric oxide synthesis and increased expression of inducible nitric oxide synthase. <i>Diabetes</i> , 1998, 47, 1602-1608.	0.3	44
149	Interleukin-1 $\beta$ -induced Rat Pancreatic Islet Nitric Oxide Synthesis Requires Both the p38 and Extracellular Signal-regulated Kinase 1/2 Mitogen-activated Protein Kinases. <i>Journal of Biological Chemistry</i> , 1998, 273, 15294-15300.	1.6	145
150	Similarities in expression levels of proteins in IL-1 $\beta$ stimulated BB-DP islets and islets syngrafted to BB-DP rats. <i>Experimental and Clinical Endocrinology and Diabetes</i> , 1997, 105, 9-9.	0.6	8
151	DEXAMETHASONE PREVENTS INTERLEUKIN-1 $\beta$ -MEDIATED INHIBITION OF RAT ISLET INSULIN SECRETION WITHOUT DECREASING NITRIC OXIDE PRODUCTION. <i>Cytokine</i> , 1997, 9, 563-569.	1.4	8
152	Interleukin-1 $\beta$ -induced nitric oxide production from isolated rat islets is modulated by D-glucose and 3-isobutyl-1-methyl xanthine. <i>European Journal of Endocrinology</i> , 1996, 134, 251-259.	1.9	32
153	Cytokines and the endocrine system. I. The immunoendocrine network. <i>European Journal of Endocrinology</i> , 1995, 133, 660-671.	1.9	66
154	Circulating interleukin-1 receptor antagonist concentrations are increased in adult patients with thermal injury. <i>Critical Care Medicine</i> , 1995, 23, 26-33.	0.4	48
155	Interleukin 1 $\beta$ induces diabetes and fever in normal rats by nitric oxide via induction of different nitric oxide synthases. <i>Cytokine</i> , 1994, 6, 512-520.	1.4	60
156	Interleukin-1 $\beta$ (IL-1) Does Not Reduce the Diabetes Incidence in Diabetes-Prone Bb Rats. <i>Autoimmunity</i> , 1994, 17, 105-118.	1.2	6
157	Nicotinamide treatment in the prevention of insulin-dependent diabetes mellitus. <i>Diabetes/metabolism Reviews</i> , 1993, 9, 295-309.	0.2	41
158	Involvement of interleukin 1 and interleukin 1 antagonist in pancreatic $\beta$ -cell destruction in insulin-dependent diabetes mellitus. <i>Cytokine</i> , 1993, 5, 185-191.	1.4	93
159	Dietary Supplementation with co-3-Polyunsaturated Fatty Acids Decreases Mononuclear Cell Proliferation and Interleukin-1 $\beta$ Content but not Monokine Secretion in Healthy and Insulin-Dependent Diabetic Individuals. <i>Scandinavian Journal of Immunology</i> , 1991, 34, 399-410.	1.3	117
160	Intra-Peritoneal Administration of Interleukin-1 $\beta$ Induces Impaired Insulin Release from the Perfused Rat Pancreas. <i>Autoimmunity</i> , 1990, 7, 1-12.	1.2	7
161	Monocyte Function in IDDM Patients and Healthy Individuals. <i>Scandinavian Journal of Immunology</i> , 1990, 32, 297-311.	1.3	62
162	Assessment of precision, concordance, specificity, and sensitivity of islet cell antibody measurement in 41 assays. <i>Diabetologia</i> , 1990, 33, 731-736.	2.9	70

#	ARTICLE	IF	CITATIONS
163	Cytokine-mediated beta-cell destruction—the molecular effector mechanism causing IDDM?. Journal of Autoimmunity, 1990, 3, 121-122.	3.0	5
164	The Autoimmune Hypothesis of Insulin-Dependent Diabetes: 1965 to the Present. E&M Endocrinology and Metabolism, 1990, , 1-28.	0.1	4
165	Cytokines as Immune Effector Molecules in Autoimmune Endocrine Diseases with Special Reference to Insulin-Dependent Diabetes Mellitus. Autoimmunity, 1989, 4, 191-218.	1.2	75
166	Genetically determined differences in newborn rat islet sensitivity to interleukin-1 in vitro: no association with the diabetes prone phenotype in the BB-rat. European Journal of Endocrinology, 1989, 120, 92-98.	1.9	8
167	Interleukin-1 potentiates glucose stimulated insulin release in the isolated perfused pancreas. European Journal of Endocrinology, 1988, 117, 302-306.	1.9	24
168	The bimodal effect of interleukin 1 on rat pancreatic beta-cells — stimulation followed by inhibition — depends upon dose, duration of exposure, and ambient glucose concentration. European Journal of Endocrinology, 1988, 119, 307-311.	1.9	90
169	Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia, 1987, 30, 474-480.	2.9	102
170	The HLA-DR3-DM1 association: Implications for etiology and pathogenesis of IDDM. Diabetes/metabolism Reviews, 1987, 3, 779-802.	0.2	93
171	Mechanisms of Pancreatic Islet Cell Destruction Dose-Dependent Cytotoxic Effect of Soluble Blood Mononuclear Cell Mediators on Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1986, 41, 250-259.	2.7	77
172	Affinity-purified human Interleukin I is cytotoxic to isolated islets of Langerhans. Diabetologia, 1986, 29, 63-67.	2.9	314
173	Low concentrations of interleukin-1 stimulate and high concentrations inhibit insulin release from isolated rat islets of Langerhans. European Journal of Endocrinology, 1986, 113, 551-558.	1.9	98
174	Increased reduction in fasting C-peptide is associated with islet cell antibodies in Type 1 (insulin-dependent) diabetic patients. Diabetologia, 1985, 28, 875-880.	2.9	86
175	Cytokines Cause Functional and Structural Damage to Isolated Islets of Langerhans. Allergy: European Journal of Allergy and Clinical Immunology, 1985, 40, 424-429.	2.7	179